Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) COO Sells 4,578 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) COO Alistair Milnes sold 4,578 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $64,504.02. Following the transaction, the chief operating officer now directly owns 100,724 shares in the company, valued at $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Bicycle Therapeutics Stock Down 0.1 %

NASDAQ BCYC traded down $0.01 during midday trading on Monday, hitting $14.88. The company had a trading volume of 289,310 shares, compared to its average volume of 435,603. The firm has a fifty day simple moving average of $19.27 and a two-hundred day simple moving average of $21.86. Bicycle Therapeutics plc has a fifty-two week low of $12.17 and a fifty-two week high of $28.67. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same period in the previous year, the business earned ($1.26) EPS. The firm’s revenue was down 50.0% on a year-over-year basis. As a group, equities analysts predict that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BCYC shares. B. Riley decreased their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Stephens assumed coverage on Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target on the stock. JMP Securities reduced their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC acquired a new stake in Bicycle Therapeutics during the 3rd quarter valued at $3,406,000. TD Asset Management Inc grew its position in Bicycle Therapeutics by 76.7% in the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after purchasing an additional 42,200 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Bicycle Therapeutics by 33.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after buying an additional 32,313 shares during the last quarter. Principal Financial Group Inc. bought a new position in Bicycle Therapeutics during the third quarter worth about $10,028,000. Finally, State Street Corp raised its position in shares of Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after purchasing an additional 60,399 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.